The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2017 | Myeloma highlights from ASCO 2017
Sagar Lonial, MD, FCAP, from the Winship Cancer Institute, Atlanta, GA, discusses some of the highlights in myeloma research presented at ASCO 2017. The first thing seen was the incorporation of antibodies into newly diagnosed myeloma. He explains that elotuzumab and daratumumab both had data presented in the combination with either carfilzomib or bortezomib. These combinations saw an improvement in the rapidity and depth of response and in both cases the antibodies were tolerated very well. The antibodies allow the addition of the fourth drug in a way that improves efficacy, improves depth of response. Another exciting area was the immunotherapy updates from the PD1 data in combination with lenalidomide and dexamethasone with very long progression free survival seen in longer follow up. Furthermore, other studies looking at the BCMA-targeted CAR T-cells have shown that BCMA may be a batter target than what CD19 was previously thought to be.
